Latest Global Growth News

Electro Optic Systems (EOS) addresses rumours about relocating its headquarters and stock listing to Europe, affirming no such decisions have been made despite strong growth in European defence markets.

Evion Group has bolstered its cash reserves to $2.3 million following a strategic placement and secured a $1.5 million expandable graphite sales agreement in the US, while advancing its Maniry Graphite Project in Madagascar with strong EU backing.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

BKI Investment Company reported a solid half-year performance with a 7% rise in operating results and a 1% increase in fully franked dividends, driven by a strategic portfolio rotation favoring resource stocks aligned with global growth themes.

Talius Group reported a positive operating cash flow for the December quarter, alongside a 3% rise in subscriptions and a $4 million capital placement. The company also announced a CEO succession and expanded its international footprint with new pilot programs.

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Temas Resources has appointed Nic Matich as a Non-Executive Director to spearhead Australian investor relations and business development, while CFO David Robinson transitions to a full-time executive role to sharpen financial oversight amid the company’s growth and commercialisation push.

Savana Asset Management’s SVNP ETF delivered a standout 12.9% net return in 2025, outperforming major US equity ETFs despite a volatile year marked by geopolitical tensions and AI-driven market narratives.

Servcorp Limited has upgraded its FY2026 profit and cash flow guidance, reflecting robust operational momentum and improved revenue efficiency across its global serviced office portfolio.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

RocketBoots Limited has slightly increased its recent capital raising, issuing an additional 100,000 shares to raise a total of A$7.025 million, reinforcing its push into international markets.